Literature DB >> 28400135

Insulin deficiency results in reversible protein kinase A activation and tau phosphorylation.

Judith M van der Harg1, Leslie Eggels2, Fabian N Bangel3, Silvie R Ruigrok4, Rob Zwart5, Jeroen J M Hoozemans6, Susanne E la Fleur7, Wiep Scheper8.   

Abstract

Alzheimer's disease (AD) is a highly prevalent multifactorial disease for which Diabetes Mellitus (DM) is a risk factor. Abnormal phosphorylation and aggregation of tau is a key hallmark of AD. In animal models, DM induces or exacerbates the phosphorylation of tau, suggesting that DM may influence the risk at AD by directly facilitating tau pathology. Previously we reported that tau phosphorylation induced in response to metabolic stress is reversible. Since identification and understanding of early players in tau pathology is pivotal for therapeutic intervention, we here investigated the mechanism underlying tau phosphorylation in the diabetic brain and its potential for reversibility. To model DM we used streptozotocin-treatment to induce insulin deficiency in rats. Insulin depletion leads to increased tau phosphorylation in the brain and we investigated the activation status of known tau kinases and phosphatases in this model. We identified protein kinase A (PKA) as a tau kinase activated by DM in the brain. The potential relevance of this signaling pathway to AD pathogenesis is indicated by the increased level of active PKA in temporal cortex of early stage AD patients. Our data indicate that activation of PKA and tau phosphorylation are associated with insulin deficiency per se, rather than the downstream energy deprivation. In vitro studies confirm that insulin deficiency results in PKA activation and tau phosphorylation. Strikingly, both active PKA and induced tau phosphorylation are reversed upon insulin treatment in the steptozotocin animal model. Our data identify insulin deficiency as a direct trigger that induces the activity of the tau kinase PKA and results in tau phosphorylation. The reversibility upon insulin treatment underscores the potential of insulin as an early disease-modifying intervention in AD and other tauopathies.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alzheimer's disease; Diabetes mellitus; Insulin deficiency; Phosphorylated tau; Protein kinase A

Mesh:

Substances:

Year:  2017        PMID: 28400135     DOI: 10.1016/j.nbd.2017.04.005

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  10 in total

1.  Alzheimer's Disease and Protein Kinases.

Authors:  Ayse Basak Engin; Atilla Engin
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  Metformin prevents p-tau and amyloid plaque deposition and memory impairment in diabetic mice.

Authors:  Wilma Helena Oliveira; Clarissa Figueiredo Braga; Deniele Bezerra Lós; Shyrlene Meiry Rocha Araújo; MariaEduarda Rocha França; Eduardo Duarte-Silva; Gabriel Barros Rodrigues; Sura Wanessa Santos Rocha; Christina Alves Peixoto
Journal:  Exp Brain Res       Date:  2021-07-20       Impact factor: 1.972

3.  Exome sequencing revealed PDE11A as a novel candidate gene for early-onset Alzheimer's disease.

Authors:  Wei Qin; Aihong Zhou; Xiumei Zuo; Longfei Jia; Fangyu Li; Qi Wang; Ying Li; Yiping Wei; Hongmei Jin; Carlos Cruchaga; Bruno A Benitez; Jianping Jia
Journal:  Hum Mol Genet       Date:  2021-05-28       Impact factor: 5.121

4.  The diabetes drug liraglutide reverses cognitive impairment in mice and attenuates insulin receptor and synaptic pathology in a non-human primate model of Alzheimer's disease.

Authors:  Andre F Batista; Leticia Forny-Germano; Julia R Clarke; Natalia M Lyra E Silva; Jordano Brito-Moreira; Susan E Boehnke; Andrew Winterborn; Brian C Coe; Ann Lablans; Juliana F Vital; Suelen A Marques; Ana Mb Martinez; Matthias Gralle; Christian Holscher; William L Klein; Jean-Christophe Houzel; Sergio T Ferreira; Douglas P Munoz; Fernanda G De Felice
Journal:  J Pathol       Date:  2018-04-02       Impact factor: 7.996

5.  Tau Phosphorylation is Impacted by Rare AKAP9 Mutations Associated with Alzheimer Disease in African Americans.

Authors:  Tsuneya Ikezu; Cidi Chen; Annina M DeLeo; Ella Zeldich; M Daniele Fallin; Nicholas M Kanaan; Kathryn L Lunetta; Carmela R Abraham; Mark W Logue; Lindsay A Farrer
Journal:  J Neuroimmune Pharmacol       Date:  2018-03-07       Impact factor: 4.147

6.  Exposure to 3-Nitropropionic Acid Mitochondrial Toxin Induces Tau Pathology in Tangle-Mouse Model and in Wild Type-Mice.

Authors:  Inbal Lahiani-Cohen; Olga Touloumi; Roza Lagoudaki; Nikolaos Grigoriadis; Hanna Rosenmann
Journal:  Front Cell Dev Biol       Date:  2020-01-14

Review 7.  Dietary exosome-miR-23b may be a novel therapeutic measure for preventing Kashin-Beck disease.

Authors:  Yujie Ning; Xi Wang; Pan Zhang; Amin Liu; Xin Qi; Meidan Liu; Xiong Guo
Journal:  Exp Ther Med       Date:  2018-02-22       Impact factor: 2.447

Review 8.  Insulin Resistance as a Therapeutic Target in the Treatment of Alzheimer's Disease: A State-of-the-Art Review.

Authors:  Christian Benedict; Claudia A Grillo
Journal:  Front Neurosci       Date:  2018-04-10       Impact factor: 4.677

Review 9.  The Dual Role of Glutamatergic Neurotransmission in Alzheimer's Disease: From Pathophysiology to Pharmacotherapy.

Authors:  Vidyasagar Naik Bukke; Moola Archana; Rosanna Villani; Antonino Davide Romano; Agata Wawrzyniak; Krzysztof Balawender; Stanislaw Orkisz; Sarah Beggiato; Gaetano Serviddio; Tommaso Cassano
Journal:  Int J Mol Sci       Date:  2020-10-09       Impact factor: 5.923

Review 10.  Metabolic Syndrome: Is It Time to Add the Central Nervous System?

Authors:  Milagros Rojas; Mervin Chávez-Castillo; Daniela Pirela; Heliana Parra; Manuel Nava; Maricarmen Chacín; Lissé Angarita; Roberto Añez; Juan Salazar; Rina Ortiz; Samuel Durán Agüero; Marbel Gravini-Donado; Valmore Bermúdez; Edgar Díaz-Camargo
Journal:  Nutrients       Date:  2021-06-30       Impact factor: 5.717

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.